Infliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritis

Modern Rheumatology

Volumn 19, Issue 6, 2009, Pages 657-662

  Kageyama, Yasunori ^a   Kobayashi, Hayato ^a   Kato, Norihiko ^a  

^a Fujieda Heisei Memorial Hospital   (Japan)

Author keywords

Infliximab; Interleukin 17; Interleukin 23; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 23; METHOTREXATE; RHEUMATOID FACTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE OF 28 C REACTIVE PROTEIN; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-17; INTERLEUKIN-23; MALE; METHOTREXATE; MIDDLE AGED; PREDNISOLONE; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 73349098712     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-009-0217-6     Document Type: Article

References (25)

1. WP Arend J-M Dayer 1995 Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis Arthritis Rheum 38 151 160 10.1002/art.1780380202 1:STN:280:DyaK2M7ltFSnsA%3D%3D 7848304
2. RN Maini PC Taylor 2000 Anti-cytokine therapy for rheumatoid arthritis Ann Rev Med 51 207 229 10.1146/annurev.med.51.1.207 1:CAS:528: DC%2BD3cXisVelsbg%3D 10774461 (Pubitemid 30216034)
3. F Ingegnoli F Fantini EG Favalli A Soldi S Griffini V Galbiati, et al. 2008 Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade J Autoimmun 31 175 179 10.1016/j.jaut.2008.07.002 1:CAS:528:DC%2BD1cXhtVymsb3M 18707846
4. V Pittoni M Bombardieri FR Spinelli R Scrivo C Alessandri F Conti, et al. 2002 Anti-tumor necrosis factor (TNF) alpha treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13 Ann Rheum Dis 61 723 725 10.1136/ard.61.8.723 1:CAS:528:DC%2BD38XmsVajurg%3D 12117680 (Pubitemid 34787711)
5. PA Klimiuk S Sierakowski I Domyslawska J Chwiecko 2004 Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis J Rheumatol 31 238 242 1:CAS:528:DC%2BD2cXhslehtLc%3D 14760791
6. T Levälampi V Honkanen P Lahdenne R Nieminen M Hakala E Moilanen 2007 Effects of infliximab on cytokines, myeloperoxidase, and soluble adhesion molecules in patients with juvenile idiopathic arthritis Scand J Rheumatol 36 189 193 10.1080/03009740601089234 17657672 (Pubitemid 47174546)
7. C Haworth FM Brennan D Chantry M Turner RN Maini M Feldmann 1991 Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha Eur J Immunol 21 2575 2579 10.1002/eji.1830211039 1:CAS:528:DyaK38XkvFKi 1915559
8. Y Kageyama M Takahashi E Torikai M Suzuki T Ichikawa T Nagafusa, et al. 2007 Treatment with anti-TNF-alpha antibody infliximab reduces serum IL-15 levels in patients with rheumatoid arthritis Clin Rheumatol 26 505 509 10.1007/s10067-006-0312-4 16680388 (Pubitemid 46359288)
9. E Torikai Y Kageyama M Suzuki T Ichikawa A Nagano 2007 The effect of infliximab on chemokines in patients with rheumatoid arthritis Clin Rheumatol 26 1088 1093 10.1007/s10067-006-0453-5 17111092 (Pubitemid 46863950)
10. K Kikly L Liu S Na JD Sedgwick 2006 The IL-23/Th(17) axis: therapeutic targets for autoimmune inflammation Curr Opin Immunol 18 670 675 10.1016/j.coi.2006.09.008 1:CAS:528:DC%2BD28XhtFens7nM 17010592 (Pubitemid 44635178)
11. F Brentano C Ospelt J Stanczyk RE Gay S Gay D Kyburz 2009 Abundant expression of the interleukin (IL)23 subunit p19, but low levels of bioactive IL23 in the rheumatoid synovium: differential expression and Toll-like receptor-(TLR) dependent regulation of the IL23 subunits, p19 and p40, in rheumatoid arthritis Ann Rheum Dis 68 143 150 10.1136/ard.2007.082081 1:CAS:528:DC%2BD1MXhslOlt7c%3D 18276743
12. E Spanakis P Sidiropoulos J Papadakis E Ganotakis G Katsikas S Karvounaris, et al. 2006 Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab J Rheumatol 33 2440 2446 1:CAS:528:DC%2BD2sXhtVCnur0%3D 17014005
13. HR Kim HS Kim MK Park ML Cho SH Lee HY Kim 2007 The clinical role of IL-23p19 in patients with rheumatoid arthritis Scand J Rheumatol 36 259 264 10.1080/03009740701286813 1:CAS:528:DC%2BD2sXps1Glsbc%3D 17763202 (Pubitemid 47346915)
14. H Mitoma T Horiuchi N Hatta H Tsukamoto S Harashima Y Kikuchi, et al. 2005 Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha Gastroenterology 128 376 392 10.1053/j.gastro.2004.11.060 1:CAS:528:DC%2BD2MXitVemsb4%3D 15685549 (Pubitemid 40431090)
15. RW Kinne R Brauer B Stuhlmuller E Palombo-Kinne GR Burmester 2000 Macrophages in rheumatoid arthritis Arthritis Res 2 189 202 10.1186/ar86 1:CAS:528:DC%2BD3cXlslyis7g%3D 11094428 (Pubitemid 32223726)
16. CA Murphy CL Langrish Y Chen W Blumenschein T McClanahan RA Kastelein, et al. 2003 Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation J Exp Med 198 1951 1957 10.1084/jem.20030896 1:CAS:528:DC%2BD3sXpvFakur4%3D 14662908 (Pubitemid 38032126)
17. L Chen XQ Wei B Evans W Jiang D Aeschlimann 2008 IL-23 promotes osteoclast formation by up-regulation of receptor activator of NF-kappa B (RANK) expression in myeloid precursor cells Eur J Immunol 38 2845 2854 10.1002/eji.200838192 1:CAS:528:DC%2BD1cXhtlOjsL7K 18958885
18. GJ Atkins DR Haynes SM Geary M Loric TN Crotti DM Findlay 2000 Coordinated cytokine expression by stromal and hematopoietic cells during human osteoclast formation Bone 26 653 656 10.1016/S8756-3282(00)00280-5 1:CAS:528:DC%2BD3cXjsVGgsL0%3D 10831938 (Pubitemid 30301659)
19. S Kotake N Udagawa N Takahashi K Matsuzaki K Itoh S Ishiyama, et al. 1999 IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis J Clin Invest 103 1345 1352 10.1172/JCI5703 1:CAS:528:DyaK1MXivFans7c%3D 10225978
20. JK Kolls A Linden 2004 Interleukin-17 family members and inflammation Immunity 21 467 476 10.1016/j.immuni.2004.08.018 1:CAS:528:DC%2BD2cXpvVygt7k%3D 15485625 (Pubitemid 39370503)
21. DJ Cua J Sherlock Y Chen CA Murphy B Joyce B Seymour, et al. 2003 Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain Nature 421 744 748 10.1038/nature01355 1:CAS:528:DC%2BD3sXhsV2rsbs%3D 12610626 (Pubitemid 36227625)
22. J Listing A Strangfeld J Kekow M Schneider A Kapelle S Wassenberg, et al. 2008 Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? Arthritis Rheum 58 667 677 10.1002/art.23281 1:CAS:528:DC%2BD1cXjslWqurw%3D 18311816
23. Y Kageyama T Ichikawa T Nagafusa E Torikai M Shimazu A Nagano 2008 Etanercept reduces the serum levels of interleukin-23 and macrophage inflammatory protein-3 alpha in patients with rheumatoid arthritis Rheumatol Int 28 137 143 10.1007/s00296-007-0388-4
24. KI Happel M Zheng E Young LJ Quinton E Lockhart AJ Ramsay, et al. 2003 Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection J Immunol 170 4432 4436 1:CAS:528:DC%2BD3sXjtVKgurw%3D 12707317
25. M Ziolkowska A Koc G Luszczykiewicz K Ksiezopolska-Pietrzak E Klimczak H Chwalinska-Sadowska 2000 High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism J Immunol 164 2832 2838 1:CAS:528:DC%2BD3cXhsVKhur0%3D 10679127